Skip to main content

Table 2 Subgroup analysis of the biochemical cure rate in patients treated with DAs and surgery treatment

From: Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis

 

DAs

Surgery

Pooled result

Number of studies

Number of patients

Pooled result

Number of studies

Number of patients

Total

0.78 (0.75, 0.82)

74

2659

0.66 (0.62, 0.71)

81

4397

Microprolactinoma

0.86 (0.78, 0.94)

9

238

0.79 (0.72, 0.85)

23

686

Macroprolactinoma

0.77 (0.72, 0.83)

27

1228

0.57 (0.46, 0.68)

15

666

Giant prolactinoma

0.62 (0.51, 0.74)

8

176

0.35 (0.08, 0.62)

3

55

1980–1989

0.74 (0.59, 0.89)

6

106

0.63 (0.52, 0.73)

15

1134

1990–1999

0.83 (0.75, 0.90)

11

397

0.64 (0.46, 0.83)

7

262

2000–2009

0.79 (0.72, 0.86)

18

605

0.69(0.60, 0.78)

20

947

2010–2019

0.77 (0.71, 0.82)

39

1551

0.67 (0.60, 0.74)

39

2054

Bromocriptine

0.70 (0.60, 0.80)

14

330

NA

NA

NA

Cabergoline

0.83 (0.78, 0.87)

32

1368

NA

NA

NA

Microscopic surgery

NA

NA

NA

0.68 (0.56, 0.80)

14

1043

Endoscopic surgery

NA

NA

NA

0.72 (0.65, 0.79)

29

1156

  1. Das dopamine agonists, NA not applicable, because the data was not discussed or calculated in the meta-analysis